Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database

Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database

Abstract Background Sorafenib has been shown to improve survival in patients with advanced hepatocellular carcinoma (HCC), however, full dose can be difficult to tolerate. The aim of this study was to determine whether sorafenib starting dose and mean dose intensity affect survival. Methods Patients...

Full description

Bibliographic Details
Main Authors: Mohammed A. Alghamdi, Carla P. Amaro, Richard Lee‐Ying, Hao‐Wen Sim, Haider Samwi, Kelvin K. Chan, Jennifer J. Knox, Yoo‐Joung Ko, Mina Swiha, Eugene Batuyong, Adriana Romagnino, Winson Y. Cheung, Vincent C. Tam, the Hepatocellular Carcinoma ‐ Cancer Health Outcomes Research Database (HCC ‐ CHORD) Consortium
Format: Article
Language:English
Published: Wiley 2020-07-01
Series:Cancer Medicine
Subjects:
discontinuation rate
dose intensity
hepatocellular carcinoma
sorafenib
starting dose
Online Access:https://doi.org/10.1002/cam4.3228

Internet

https://doi.org/10.1002/cam4.3228

Similar Items